Study Shows Ivermectin Not Recommended for Treatment of COVID-19

February 24, 2022 by Alexa Hornbeck
Study Shows Ivermectin Not Recommended for Treatment of COVID-19

A new study released this week in JAMA Internal Medicine finds ivermectin, an antiparasitic drug, has failed to treat individuals with COVID-19.  

To conduct the open-label study, researchers enrolled high-risk patients with COVID-19 from 20 public hospitals and COVID-19 quarantine centers in Malaysia between May 31 and October 25, 2021. 

The patients were randomized to receive either oral ivermectin for five days plus standard of care, or standard of care without ivermectin for five days, which was administered during the first week of illness. The researchers found the treatment did not reduce the risk of developing severe disease compared with the standard of care. 


Among the 490 patients included in the analysis, 21.6% in the ivermectin group and 17.3% in the control group progressed to severe disease and for all secondary outcomes there were no significant differences between the groups. 



Despite these findings, which indicate that ivermectin should not be a factor in treatment decisions, researchers say the inexpensive and widely available treatment remains popular because of certain political backing.

Alexa can be reached at [email protected]

A+
a-

In The News

Health

Voting

Health

Schools Struggle to Staff Up for Youth Mental Health Crisis

Mira Ugwuadu felt anxious and depressed when she returned to her high school in Cobb County, Georgia, last fall after... Read More

Mira Ugwuadu felt anxious and depressed when she returned to her high school in Cobb County, Georgia, last fall after months of remote learning, so she sought help. But her school counselor kept rescheduling their meetings because she had so many students to see. “I felt... Read More

November 17, 2022
by Dan McCue
FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute... Read More

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute onset of pancreatitis in dogs.  Panoquell-CA1 is an injectable drug intended for use while the dog is hospitalized for treatment of the disease.   Pancreatitis is a... Read More

November 15, 2022
by TWN Staff
Case Western Reserve University Awarded $7.3M for Eye Research

CLEVELAND — Case Western Reserve University School of Medicine has been awarded a five-year, $7.3 million grant from the National... Read More

CLEVELAND — Case Western Reserve University School of Medicine has been awarded a five-year, $7.3 million grant from the National Institutes of Health to identify new technology, methods and models to study the impact of inflammation and pain on the surface of the eye. “The cornea... Read More

November 15, 2022
by TWN Staff
Improved Eye Care Could Have Prevented Dementia Cases, Study Says

WASHINGTON — A study recently published in the journal JAMA Neurology suggests that as many as 100,000 U.S. dementia cases... Read More

WASHINGTON — A study recently published in the journal JAMA Neurology suggests that as many as 100,000 U.S. dementia cases could possibly have been prevented with improved eye care. The National Institute on Aging-funded research used data from a University of Michigan Health Retirement Study that... Read More

November 15, 2022
by Dan McCue
Google Pilot Testing Health Care Records Tool

Google is pilot testing the integration of its Google Care Studio search tool into the health records of two health... Read More

Google is pilot testing the integration of its Google Care Studio search tool into the health records of two health systems, one in Alabama and the other in Wisconsin. According to a recent JAMA Network Open study, poor access to the information clinicians need is leading... Read More

November 15, 2022
by Dan McCue
Report Finds Cancer Deaths Continue Downward Trend

WASHINGTON — The death rate from most cancers continued to decline over a four-year period extending from 2015 to 2019,... Read More

WASHINGTON — The death rate from most cancers continued to decline over a four-year period extending from 2015 to 2019, according to the latest Annual Report to the Nation on the State of Cancer from the National Institutes of Health. During roughly the same period, the... Read More

News From The Well
scroll top